{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:46:44Z","timestamp":1791841604840,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K16768"],"award-info":[{"award-number":["25K16768"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy OPEN"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.hpopen.2026.100181","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:11:50Z","timestamp":1787242310000},"page":"100181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Yuto","family":"Yoshinaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpopen.2026.100181_bb0005","unstructured":"European Social Insurance Platform, Medicine Evaluation Committee. Trends in pharmaceutical expenditure October 2024. 2024. https:\/\/publicpharmaforeurope.org\/trends-in-pharmaceutical-expenditure\/ (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0010","unstructured":"The White House. Fact sheet: President Donald J. Trump announces actions to put American patients first by lowering drug prices and stopping foreign free-riding on American pharmaceutical innovation. 2025. https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/05\/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation\/ (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0015","unstructured":"Yokote K. National university hospital directors\u2019 press conference [in Japanese]. 2022. https:\/\/nuh-forum.umin.jp\/report\/kaigi\/pdf\/221207.pdf (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"10.1016\/j.hpopen.2026.100181_bb0025","article-title":"R&D costs of new medicines: A landscape analysis","volume":"8","author":"Simoens","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.hpopen.2026.100181_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and research and development intensity in the US, 2000-2018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hpopen.2026.100181_bb0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd1382","article-title":"Key factors in the rising cost of new drug discovery and development","volume":"3","author":"Dickson","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hpopen.2026.100181_bb0040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"How much does it cost to research and develop a new drug? A systematic review and assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.hpopen.2026.100181_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11151-006-0010-z","article-title":"The determinants of pharmaceutical R&D expenditures: evidence from Japan","volume":"28","author":"Mahlich","year":"2006","journal-title":"Rev Ind Organ"},{"key":"10.1016\/j.hpopen.2026.100181_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103726","article-title":"Analysis of pharma R&D productivity - a new perspective needed","volume":"28","author":"Schuhmacher","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.hpopen.2026.100181_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrd1633","article-title":"Pricing medicines: theory and practice, challenges and opportunities","volume":"4","author":"Gregson","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hpopen.2026.100181_bb0060","unstructured":"Ministry of Health, Labour and Welfare. Criteria for calculating pharmaceutical prices [in Japanese]. 2026. https:\/\/www.mhlw.go.jp\/content\/001706542.pdf (accessed July 23, 2026)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21423\/JRS-V08SHOYO","article-title":"Japanese pharmaceutical industry: recent perspectives and areas for further research","volume":"8","author":"Shibata","year":"2020","journal-title":"Regsci"},{"key":"10.1016\/j.hpopen.2026.100181_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1377\/hlthaff.18.3.56","article-title":"Health care reform in Japan: the virtues of muddling through","volume":"18","author":"Ikegami","year":"1999","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.hpopen.2026.100181_bb0075","unstructured":"AGS Consulting Co., Ltd., AGS Certified Tax Co. AGS healthcare management information [in Japanese]. 2024. https:\/\/www.agsc.co.jp\/cms\/wp-content\/uploads\/2024\/02\/8edb3d0e29c4673e65534cfe3c9dfc98.pdf (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0080","unstructured":"Japan Hospital Association, All Japan Hospital Association, Association of Japanese Healthcare Corporations. 2023 hospital management periodic survey summary version - Final report: Aggregate results [in Japanese] 2023. https:\/\/www.ajha.or.jp\/voice\/pdf\/231130_2.pdf (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.healthpol.2012.01.002","article-title":"Effects of the per diem prospective payment system with DRG-like grouping system (DPC\/PDPS) on resource usage and healthcare quality in Japan","volume":"107","author":"Hamada","year":"2012","journal-title":"Health Policy"},{"key":"10.1016\/j.hpopen.2026.100181_bb0090","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/13696998.2024.2427502","article-title":"Value-based reimbursement under the inpatient prospective payment system in Japan: A review of Japan\u2019s diagnosis procedure combination\/per-diem payment system","volume":"27","author":"LoPresti","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.hpopen.2026.100181_bb0095","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Overview of the 2024 medical fee schedule revision [inpatient care category V (DPC\/PDPS, short-stay surgery, etc.)] [in Japanese]. 2024. https:\/\/www.mhlw.go.jp\/content\/12400000\/001221678.pdf (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0100","unstructured":"Ministry of Health, Labour and Welfare. About special functioning hospitals [in Japanese]. n.d. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000137801.html (accessed May 19, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0105","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/1468-0009.12714","article-title":"A comparative analysis of international drug price negotiation frameworks: an interview study of key stakeholders","volume":"102","author":"Syversen","year":"2024","journal-title":"Milbank Q"},{"key":"10.1016\/j.hpopen.2026.100181_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/bst.2023.01027","article-title":"Comparison of diagnosis-related groups (DRG)-based hospital payment system design and implementation strategies in different countries: the case of ischemic stroke","volume":"18","author":"Liu","year":"2024","journal-title":"Biosci Trends"},{"key":"10.1016\/j.hpopen.2026.100181_bb0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1536867X19830877","article-title":"Fast and wild: bootstrap inference in Stata using boottest","volume":"19","author":"Roodman","year":"2019","journal-title":"Stata J"},{"key":"10.1016\/j.hpopen.2026.100181_bb0120","unstructured":"Ministry of Health, Labour and Welfare. Survey on the actual state of medical economics (survey of medical institutions, etc.) [in Japanese]. n.d. https:\/\/www.mhlw.go.jp\/bunya\/iryouhoken\/database\/zenpan\/iryoukikan.html (accessed July 27, 2025)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0125","unstructured":"Nikkei Inc. FinancialQUEST [in Japanese]. n.d. https:\/\/needs.nikkei.co.jp\/services\/financial-quest\/ (accessed December 24, 2024)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0130","unstructured":"I-N Information Systems, Ltd. eol [in Japanese]. n.d. https:\/\/www.indb.co.jp\/service\/corporate_data\/eol\/ (accessed December 24, 2024)."},{"key":"10.1016\/j.hpopen.2026.100181_bb0135","first-page":"14","article-title":"Organizational and environmental factors associated with hospital financial performance: A systematic review","volume":"43","author":"Oner","year":"2016","journal-title":"J Health Care Finance"},{"key":"10.1016\/j.hpopen.2026.100181_bb0140","first-page":"39","article-title":"Aggregate earnings and why they matter","volume":"34","author":"Ball","year":"2015","journal-title":"J Account Lit"},{"key":"10.1016\/j.hpopen.2026.100181_bb0145","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s11142-020-09536-x","article-title":"Negative accounting earnings and gross domestic product","volume":"25","author":"Gaertner","year":"2020","journal-title":"Rev Acc Stud"},{"key":"10.1016\/j.hpopen.2026.100181_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacceco.2016.04.003","article-title":"Aggregate earnings surprises, monetary policy, and stock returns","volume":"62","author":"Gallo","year":"2016","journal-title":"J Account Econ"},{"key":"10.1016\/j.hpopen.2026.100181_bb0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2308\/TAR-2020-0459","article-title":"International financial reporting standards and the macroeconomy","volume":"99","author":"Kausar","year":"2024","journal-title":"Account Rev"},{"key":"10.1016\/j.hpopen.2026.100181_bb0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacceco.2013.10.001","article-title":"Accounting earnings and gross domestic product","volume":"57","author":"Konchitchki","year":"2014","journal-title":"J Account Econ"},{"key":"10.1016\/j.hpopen.2026.100181_bb0165","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2308\/accr-50632","article-title":"Taking the pulse of the real economy using financial statement analysis: implications for macro forecasting and stock valuation","volume":"89","author":"Konchitchki","year":"2014","journal-title":"Account Rev"},{"key":"10.1016\/j.hpopen.2026.100181_bb0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2308\/accr-51714","article-title":"Why does aggregate earnings growth reflect information about future inflation?","volume":"92","author":"Shivakumar","year":"2017","journal-title":"Account Rev"},{"key":"10.1016\/j.hpopen.2026.100181_bb0175","first-page":"196","article-title":"Aggregate earnings informativeness and economic shocks: international evidence","volume":"30","author":"Yoshinaga","year":"2023","journal-title":"Asia-Pac J Account Econ"},{"key":"10.1016\/j.hpopen.2026.100181_bb0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/abac.12071","article-title":"Accounting valuation and cost of capital dynamics: theoretical and empirical macroeconomic aspects. Discussion of Callen","volume":"52","author":"Konchitchki","year":"2016","journal-title":"Abacus"},{"key":"10.1016\/j.hpopen.2026.100181_bb0185","article-title":"Justification for financial support of unprofitable district hospitals in Japan: an empirical analysis","volume":"12","author":"Yoshinaga","year":"2025","journal-title":"Soc Sci Humanit Open"}],"container-title":["Health Policy OPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229626000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229626000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:07:34Z","timestamp":1791839254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590229626000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S2590229626000213"],"URL":"https:\/\/doi.org\/10.1016\/j.hpopen.2026.100181","relation":{},"ISSN":["2590-2296"],"issn-type":[{"value":"2590-2296","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis","name":"articletitle","label":"Article Title"},{"value":"Health Policy OPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpopen.2026.100181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100181"}}